Dupilimab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Asthma by Body Mass Index

Conclusion: Dupilumab reduced severe exacerbations and improved FEV1 in pts with uncontrolled, moderate-to-severe asthma, regardless of BL BMI or DPL dose received.

Source: European Respiratory Journal - November 20, 2019 Category: Respiratory Medicine Authors: Korn, S., Busse, W. W., Echave-Sustaeta, J. M., Dixon, A. E., Mucsi, J., Rice, M. S., Deniz, Y., Rowe, P., Staudinger, H. W., Amin, N., Ruddy, M., Graham, N. M. H., Teper, A. Tags: Allergy and immunology Source Type: research